After After
Before Before

10051 - 5LO, Arteriosclerosis

INTRODUCTION

This APP has been developed to quantify the occurrence of immunohistochemically detectable 5-lipoxygenase (5LO) in atherosclerotic plaques, irrespective of its cellular or extracellular location.

Lipoxygenases are a family of iron-containing enzymes that catalyze the deoxygenation of polyunsaturated fatty acids. 5LO is expressed in inflammatory cells of the myeloid line, such as histiocytes (including foam cells), dendritic reticular cells, mast cells and granulocytes. In resting myeloid cells, 5LO resides in the cytoplasm or the nucleoplasm, but when activated relocates to the nuclear membrane. 5LO is involved in the metabolism of the cell membrane derived arachidonic acid leading to formation of 4-series leukotrienes (LTs) which are major contributors to inflammatory reactions.

In arteriosclerotic disease LTs may enhance the formation of atherosclerotic plaques as well as plaque instability by effects on leukocyte chemotaxis, vascular inflammation and subsequent matrix degeneration. Important clinical endpoints have been studied in genetic association studies, where polymorphisms in the 5LO encoding gene (ALOX5) have been linked to increased risk of myocardial infarction, stroke and increased carotid intima and media thickness.

The expression of 5LO in advanced atherosclerotic plaque seems to be co-localized with CD68 positive macrophages/foam cells/dendritic reticular cells. Apart from mast cells in adventitia, other myeloid cell types contribute very little to the 5LO positive population in the arterial wall. 5LO-positive histiocytes localize to the adventitia in areas of neoangiogenesis and constitute a main component of arteriosclerotic aneurysms.

The rabbit monoclonal antibodies G590.2 (Thermo Scientific) and C49G1 (Cell Signaling) are both useful. Heat induced epitope retrieval (HIER) is mandatory; an alkaline buffer should be preferred. For the Ventana platform, HIER should be followed by a short (3-4 min) proteolytic pre-treatment.
As control tissues, tonsil and liver are useful: In the tonsil, mantle zone B-lymphocytes must show a moderate nuclear reaction, and in the liver, the Kupffer cells must show a moderate cytoplasmic reaction.

KEYWORDS

5LO, arteriosclerosis, atherosclerotic plaques.

METHODS

The first image processing step involves a segmentation of background, tissue, negative and 5LO positive nuclei, [See EXAMPLES: figure 3]. Next a post-processing step is applied to remove background, tissue and negative nuclei [See EXAMPLES: figure 4]. Additionally, 5LO positive nuclei are separated into two groups based on their area (below and above 10 µm2) and nuclei with a too low staining intensity are removed. The image obtained after post-processing [See EXAMPLES: figure 5] is used to determine the output variables.

Tissue is outlined as ROI automatically using an auxiliary APP. It is possible to modify the ROI outline with the layer drawing tool. This may be necessary if damaged tissue is present in the ROI.


QUANTITATIVE OUTPUT VARIABLES

Segmented nuclei are categorized in nuclei of area above and below 10 µm2. The output variables of the protocol include measurements from the two groups of nuclei and a total of these:

- TISSUE (A): Area of Tissue:

- POS BELOW (N): Number of positive nuclei profiles below 10 µm2

- POS ABOVE (N): Number of positive nuclei profiles above 10 µm2

- POS NUCLEI (N): Total number of positive nuclei profiles

- % POS BELOW (A) = (POS BELOW (A)) / (TISSUE (A)) * 100: Positive area ratio below 10 µm2

- % POS ABOVE (A) = (POS ABOVE (A)) / (TISSUE (A)) * 100: Positive area ratio above 10 µm2

- % POS NUCLEI (A) = (POS NUCLEI (A)) / (TISSUE (A)) * 100: Positive area ratio


AUXILIARY APPS (included)

Auxiliary APPs are used for additional process steps, e.g. finding Region of Interest (ROI).

An Auxiliary APP is used to segment and outline the tissue as ROI. The Auxiliary APP must run before the nuclei detection APP is applied.


STAINING PROTOCOL

There is no staining protocol available.


ADDITIONAL INFORMATION

This APP was developed in cooperation with Professor Mogens Vyberg from NordiQC and Aalborg University Hospital.

The APP utilizes the EngineTM and Viewer software modules, where EngineTM offers an execution platform to expand processing capability and speed of image analysis. Viewer gives a fast review together with several types of image adjustment properties ex. outlining of regions, annotations and direct measures of distance, curve length, radius, etc.
By adding the AuthorTM module the APP can be customized to fit other purposes. AuthorTM offers a comprehensive and dedicated set of tools for creating new fit-for-purpose analysis APPs, and no programming experience is required.


REFERENCES

USER

This APP was developed in cooperation with Professor Mogens Vyberg from NordiQC and Aalborg University Hospital.

LITERATURE

1. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis, M. Bäck , Curr Pharm Des. 15(27): 3116-32, 2009. PubMed PMID: 19754386.

2. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis, J. H. Dwyer et al., N Engl J Med. Jan 1 350(1): 29-37, 2004. PubMed PMID: 14702425.

3. Association between 5-lipoxygenase expression and plaque instability in humans, F. Cipollone et al., Arterioscler Thromb Vasc Biol. Aug 25 (8): 1665-70, 2005. PubMed PMID: 15933245.

4. Thegene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke, A. Helgadottir et al., Nat Genet. Mar 36(3): 233-9, 2004. PubMed PMID: 14770184.

5. Leukotrienes, M. Peters-Golden et al., N Engl J Med. Nov 1 357(18): 1841-54, 2007. PubMed PMID: 17978293.

6. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability, H. Qiu et al., Proc Natl Acad Sci USA May 23 103(21): 8161-6, 2006. PubMed PMID: 16698924; PubMed Central PMCID: PMC1459628.

7. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis, R. Spanbroek et al., Proc Natl Acad Sci USA Feb 4 100(3): 1238-43, 2003. PubMed PMID: 12552108; PubMed Central PMCID: PMC298757.

8. Lipoxygenase pathways in atherogenesis, L. Zhao et al., Trends Cardiovasc Med Jul 14(5): 191-5, 2004. PubMed PMID: 15261891.

9. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm, L. Zhao et al., Nat Med Sep 10(9): 966-73, 2004. PubMed PMID: 15322539.

RUO
FIGURE 1
FIGURE 1
Original Image at 1x after the tissue automatically has been segmented and outlined as ROI.
FIGURE 2
FIGURE 2
40x Field of view showing the tissue with positive and negative nuclei before segmentation.
FIGURE 3
FIGURE 3
40x Field of view showing the segmented positive nuclei with a green label.
FIGURE 4
FIGURE 4
40x Field of view showing segmented positive nuclei. Green label indicating nuclei with area below 10 µm2. Red label indicating nuclei with area above 10 µm2.